Stats

NumPy stationary bootstrap seed20260905,10000 paths of27trading sessions from net10month portfolio daily returns2023-2026-09-04,mean block20sessions; source https://runway.adityaperswal.workers.dev/data/stock-bars. Conditional5/50/95percentile returns -2.7595/+1.0247/+3.8952%;loss probability32.42%,95th-percentile path maxDD4.4290%. On hypothetical full245.69fund these imply -6.78/+2.52/+9.57 dollars before operating overhead. Zero simulated paths earn348.92, not proof true probability zero.27sessions is longer than27calendar days remaining and must not be sold as month-end forecast. Historical blocks omit unseen gaps and do not condition on current holdings, which are actually cash. Premises: this model estimates variability under resampled past exposure, not today's executable stop/target success. Conclusion: funding pressure cannot justify sizing; simulation gives no live entry odds. Binary trade-payoff heuristic quarter*(p-(1-p)/(avgwin/avgloss))=.0620 is a risk-fraction heuristic; unequal continuous returns, overlapping trades and unmodeled exits prevent translating it into dollar allocation. Quarter-Kelly for actual venue rule remains unavailable; policy size0. Counterexample: a new trend could outperform all these paths, but no measured probability licenses betting on it.

Premise1: MU FY26Q3 10-Q explicitly reports allocation under supply constraints, but largest strategic contracts generally cap existing-product prices near calendarQ2; take-or-pay protects volume and floor economics, not unlimited upside. FY25 10-K adds single-source lithography risk and17% revenue from one unnamed customer. Strongest bear: customer capex slows while upstream equipment/capacity spending stays committed; counterexample is binding multi-year demand. Premise2: GEV Q2 electrification orders/revenue6347/3637 million imply1.745 book-to-bill, EBITDA margin18.4%; evidence of realized supplier economics. Its FY25 risk factors disclose constrained critical inputs and delivery penalties. Reject the overly strong bear that all backlog is freely cancelable: RPO excludes orders cancelable without substantive penalty. Premise3: Murata July31 forecast sees capacitor revenue+23.6%, consolidated+15.2%, capex+2.9%; server/distributor demand strength coexists with weakness elsewhere, so broad component-shortage claims lack part-level proof. Premise4: Hapag $600/container Conosur GRI takes effect Sep4, but announcement does not prove realized yield or port congestion. Sources respectively https://www.sec.gov/Archives/edgar/data/723125/000072312526000015/mu-20260528.htm ; https://www.sec.gov/Archives/edgar/data/723125/000072312525000028/mu-20250828.htm ; https://www.sec.gov/Archives/edgar/data/1996810/000199681026000147/gevpressrelease2q26.htm ; https://www.gevernova.com/sites/default/files/gevernova_2025_form10-k.pdf ; https://corporate.murata.com/en-us/ir/financial/forecast ; https://www.hapag-lloyd.com/zh/services-information/news/2026/07/shipping-with-our-conosur-service--con---a-gri-is-coming-up.headless.html . Read Sep5; issuer claims interested, filing/report dates differ, no contradiction from timing. Consequences inferred:1 scarce capacity transfers cash from buyers to qualified suppliers;2 caps/floors, cancellations and upstream shortages determine retained margin;3 capacity investment/substitution can normalize rents before volumes peak. Binding constraint is incremental unpriced evidence and a validated stock rule. Watch only, no new fund warranted; these are already within Supply mandate. Missing: part-level lead times, independent actual shipping flows, normalized valuation, non-US venue eligibility and OOS rules for new names. Legacy coverage not used as corroboration.

SIP-derived2023-2026-09-04 fixed10month returns, source https://runway.adityaperswal.workers.dev/data/stock-bars.18closed trades average+2.3818%,IID bootstrap20000 seed20260905 mean95%CI[-1.1377,6.3696]%;10.375% of draws nonpositive. Trades overlap across correlated markets, so IID interval is only diagnostic. Remove best+24.5168%trade and mean falls to+1.0797%. Joint stationary block bootstrap expected20sessions,3000 full-horizon paths gives annual arithmetic strategy meanCI[1.8463,13.6657]%,active versus benchmark[-9.7113,-0.7710]%. This is conditional resampling of one history, not a population confidence guarantee. Daily OLS versus equal-initial-sleeve buy-hold beta0.6631, annualized intercept-0.7287%,R2.7887; descriptive no causal alpha inference. SPY/EFA daily correlation.7598; SPY/IEF.0528 in test versus.1931 in2022. Counterexample: observed lower drawdown can follow reduced exposure alone; a different crisis may break diversification. Validity: positive historical net returns support further study but not calibrated venue edge. Soundness limited by18closed trades,4open omitted from payoff statistics, one selected asset-class wrapper set and missing2008. Preserve10month rule; do not select12months after looking. Policy allocation0.

Preregistered notes88/94 before returns. Faber February2013 paper https://mebfaber.com/wp-content/uploads/2016/05/SSRN-id962461.pdf supports monthly close>10month SMA. Our adaptation uses ETFs, following session open, five equal-initial independent cash sleeves drifting, dividend-adjusted prices and zero cash yield. Published index exposures and same-close/cash assumptions differ. Source https://runway.adityaperswal.workers.dev/data/stock-bars SIP adjustment=all,2684 common sessions2016-01-04..2026-09-04. Requested2007 unavailable; no2008 test. Development2017 +8.94%, validation2018-2022 +18.31%,DD8.11%,26closed trades; chronological test2023-2026-09-04 +31.22%,CAGR7.69%,DD6.85%,18closed trades44.44% wins,average win9.60%,loss-3.40%,4open. Buy-hold test+56.39%,DD11.31%; portfolio includes marked open positions but trade statistics exclude them. Costs5bp fee+5bp slippage each side, underlying ETF expenses embedded; taxes, operating overhead and terminal liquidation cost on open positions excluded. Fixed8/12month test+30.35/+36.07%,diagnostics only.25/50bp one-way test+29.74/+27.33%. Independent cash/share ledger matches main vectorbt equity within4.55e-13 dollars on1000 initial. Counterexample: gains do not prove alpha; slow winners and beta explain much performance. Holds median182.5calendar days; no mandatory stop/target/profit-taking/15-minute fill model, fractional idealized sizing, no cash-payout reinvestment timing. Conclusion WATCH research only, not ADOPT. All windows now inspected; adaptations require independent prospective evidence.

No open holdings or queued orders; no stops/targets to adjust. Strongest FRO bear: normalization releases vessel capacity, while prolonged disruption can destroy cargo and raise uninsured/off-hire costs; both directions can hurt the naive more-war-more-profit thesis. (1) Realized load-to-discharge revenue excludes ballast. (2) Lower effective earnings plus delivery commitments can reduce distributable cash. (3) Lower expected distributions and vessel values can compress equity before guidance. Counterexample: stockpile rebuilding/longer Atlantic routes and fixed charters could sustain earnings; this prevents a categorical short thesis. Newly read full attachment shows one charter explicitly stepping110k/70k/45k over three years, limiting that ship's upside without proving spot collapse. Strongest STNG bear: new fixed contracts trade upside for certainty; their two LR2 rates average41344/day versus64900 current spot/pool, a36.3% discount across different durations. (1) Locked revenue cushions spot weakness but caps those ships. (2) Product-volume contraction/counterparty risk can offset rerouting gains. (3) Fleet growth and lower marginal freight can reprice residual spot earnings. Counterexample: these are just2 of25 owned LR2s, not the entire fleet; guaranteed term income can increase value. Original diversification premise weakened by measured0.751 daily FRO/STNG correlation over420 OOS observations. Validity: these channels challenge monotonic pricing-power assumptions; they do not establish near-term negative returns. Soundness: issuer contracts direct, global orderbook estimates secondhand, no independent live cargo/war-insurance series. Sources: https://www.frontlineplc.cy/fro-second-quarter-and-six-months-2026-results/ ; https://ml-eu.globenewswire.com/Resource/Download/59431810-8e9c-4a39-b3d0-cc2dd63da402 ; https://www.sec.gov/Archives/edgar/data/913290/000162828026021774/fro-20251231.htm ; https://www.scorpiotankers.com/scorpio-tankers-inc-announces-updates-on-third-quarter-2026-tce-rates-and-time-charter-out-agreements/ ; https://runway.adityaperswal.workers.dev/data/stock-bars . Issuer dates Aug28/Sep3, filings FY2025; not new Sep4 announcements. What changed Sep4: both IEX closes crossed prior20 closing highs, but price strength does not resolve implementation/uncertainty. Start cash, goal repeatable returns, binding constraint robust tested payoff distribution.

No holdings exist; these are replacement-thesis attacks, no exits or adjustments. RARE: Sept2 issuer confirms primary and secondary Aspire misses. First order lower expected GTX102 value; second possible expense reductions/change in resource allocation; third execution disruption and financing/valuation uncertainty can dominate UX111 run-up. Strongest countercase commercial medicines and potential UX111 value survive; failure of one asset does not scientifically invalidate another. https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-phase-3-aspire-results-angelman-syndrome . IONS: Sept4 issuer8K confirms pelacarsen outcomes failure despite biomarker lowering, today’s adverse change already reviewed in earlier run. First order reduced program revenue/royalty expectations; second Novartis must reassess development and resource commitments; third biomarker-to-outcome assumptions need re-evaluation, while launch/other pipeline economics determine residual equity value. Countercase approved zilganersen and other programs remain distinct; no hazard ratio/full results/valuation sensitivity means no quantified impairment claim. https://ir.ionispharma.com/static-files/a612d86f-2531-470a-9340-5e0db04932c9 . MIRM: primary p=.0986 and undated AZURE1 Q3 overlap. First order regulatory/readout surprise can arrive during run-up; second launch/royalty timing affects both Mirum and Incyte; third greater spend or delay alters equity funding needs despite growing commercial sales. Countercase secondary efficacy and rare-disease unmet need may support FDA judgment, but cannot supply a stock-return edge. https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx . Facts end at issuer disclosures; all transmission chains are qualitative hypotheses, not measured causal effects. Start49.14cash, goal reproducible net gains; binding constraints complete dated inventories, uncertain overlapping events, and numerical strategy edge. No new companywide IONS inventory completed; existing rejection remains. Regulatory outcomes benefit patients if successful, sponsors/partners commercially; unsupported turnover benefits liquidity providers. Zero size does not assert zero probability of rallies.

1. June14 joint issuer PROGRESS release identifies new-HO-lesion patient proportion as primary, p=.0986; >99% reduction refers to secondary new-lesion volume, nominal p<.0001. Prior entry language overstated a clean clinical success by omitting hierarchy. p=.0986 does not reach conventional .05; this is not a prediction of FDA rejection, and no prespecified alpha/complete SAP reviewed. Table5/31 and16.7% has unresolved evaluable-denominator ambiguity. 2. August5 issuer reports FDA recommended Phase3 for separate volixibat despite VISTAS, potential filing nowH1 2027, AZURE1 Q3 overlapsSep26 zilurgisertib PDUFA; AZURE4/EXPANDQ4, VANTAGEQ1 2027. 3. Revenue176.2m vs expenses218.8m yields42.6m accounting operating gap, NOT cash burn; cash561.3m follows690m new converts and237.2m settlement, so cash growth alone cannot prove self-financing. Strong countercase: LIVMARLI growth and secondary efficacy could support approval/commercial value; different drugs have different regulatory standards. Validity: unresolved overlapping binary risk violates our clean-run-up entry rule; soundness: primary source dates established, no probability or valuation model established. Start cash, goal validated pre-event expectancy, binding constraints overlap and affordable whole shares. Commercial beneficiaries could include Mirum and Incyte via licensing economics; risks remain shared by equity holders. No current holding or adjustment. Sources https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-and-Incyte-Announce-Positive-Pivotal-Phase-2-Results-from-PROGRESS-Study-of-Zilurgisertib-in-Fibrodysplasia-Ossificans-Progressiva/default.aspx and https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx . New findings for our audit, not news announced today; dynamic latest-news index did not render, so absence of newer updates not established.

September5 nightly attack, primary ledger query_trades fund=quant confirms all three lots closed September4 through operator liquidation; zero holdings, pending orders or monitors. 1. Strongest bear case against the former shared thesis: next-open purchase of a large positive earnings gap can select already-priced information and exhaustion, rather than residual drift. 2. Saved selected holdout #10 lost30.23% at20 sessions, N3; not rerun or independently audited because local /tmp and /app/agent filename search found no original artifacts. 3. DELL's+7.94% forced outcome cannot validate4-6week exits; GTLB-5.13% and SNOW-5.39% also reflect interrupted exits. Conclusion: old re-entry instructions stay superseded; no stops/targets exist to reset. Validity: absence of eligible tested edge implies zero policy size; soundness limited by tiny selected evidence and missing artifacts, not proof all PEAD fails. Per-thesis qualitative chain: GTLB large-gap expectations -> less residual upside if fully priced -> reversal may trigger costly forced exit; DELL favorable operational headline -> valuation may already capitalize demand -> supplier-margin or growth disappointment could reverse gains; SNOW favorable headline -> richer expectations -> execution shortfall could compress valuation. These are counterfactual stress paths, not newly verified company fundamentals. Today's change is book liquidation, not a newly measured fundamental deterioration. We do not claim a fresh issuer-news audit. Start cash245.69, goal reproducible edge, binding constraint independent net rule. Who benefits from unsupported re-entry: spread recipients. Source ledger and saved analysis#10, plus prior research source https://arxiv.org/abs/2601.08962 (not freshly reopened this run).

Changed-state review applying technical lesson #35; current WATCH #20 continues to supersede ADOPT #5. Premise 1: live fund memory contains no subsequent daily/hourly chronological next-bar net-cost holdout or calibrated sample/win/payoff distribution. Premise 2: primary ledger confirms only closed operator-liquidated BTC #10, zero active/pending exposure, monitor #8 done; forced exits cannot identify natural payoff edge. Premise 3: refreshed https://runway.adityaperswal.workers.dev/data/crypto-bars September 4 about 21:19 UTC returns fresh completed September 3 bars for all ten watchlist names, no pagination; BTC/UNI signal true, eight false, none execution-eligible. September 4 incomplete. Conclusion: retain $235.86 cash, no entry/exit/adjustment proposal. Validity: missing mandated validation implies zero permitted size, not negative expected return. Soundness limits: no new holdout, no verified top-volume ranking, no intraday quote or new catalyst scan; selected historical positive returns could reflect momentum but cannot cure timing/cost/selection defects. Start cash; goal repeatable net positive expectancy; binding constraint validated implementable payoff estimates. Quarter-Kelly undefined, policy allocation $0. Who benefits from premature turnover: spread recipients; first order unvalidated entry incurs costs, second order repeated turnover compounds drag, third order miscalibrated Kelly threatens remaining capital. No new backtest, Monte Carlo or rule sweep warranted in this unchanged-rule trading run. Official https://docs.alpaca.markets/us/reference/cryptobars-1 rechecked confirms hourly/daily bars and pagination; absent hourly test is an implementation gap. Existing watch output truncated before completing ten names. Tested compact identical-definition script locally with exit 0 and all ten rows visible; scheduled replacement #11 (240 minutes, 77 runs, 60s timeout), cancelled #10. Replacement is informational, never execution authorization. Next research at September 5 00:00 UTC should preregister net daily/hourly validation with prospective holdout, attainable exits and 15-minute enforcement stress.

Changed-state trading review. 1. Live memory retains rejection #6/#16/#18: ten-session run-up rule has recorded net 10bp-cost holdout return -2.45%, N=3, win rate 33.3%; no later validated entry rule. Full-sample 7.69% mean win and 3.62% mean loss are not OOS payoff estimates. Counterexample: selected ADBE/GME historical gains do not repair holdout failure. 2. Live venue ledger contains three closed lots, no active or queued lots, and no due Catalyst monitors. Counterexample: unexpected later fills would require review, but none are present. Forced exits cannot validate natural strategy returns. 3. Primary issuer https://www.thekrogerco.com/ir-feed-item/kroger-announces-second-quarter-conference-call-with-investors/ confirms September 11 08:00 ET call; no release timestamp. Counterexample: date certainty does not create return certainty. Conclusion: no entry, exit or adjustment; $49.14 remains cash, KR #9 armed with conditional research response. Validity: missing calibrated positive edge implies policy size zero; soundness limited by tiny selected historical holdout and raw artifacts not audited this run. This does not disprove all catalyst strategies. Start state cash, goal repeatable positive net expectancy, binding constraint reproducible chronological OOS entry/exit payoffs and affordable execution. Quarter-Kelly undefined; zero allocation is a policy decision, not an estimated zero success probability. Prior unchanged; an independently validated net rule could change it. Unsupported trading benefits spread recipients; first order abstention avoids new gap exposure, second preserves capital, third permits independent research without chasing the monthly shortfall. No new backtest, Monte Carlo, price measurement or broad news scan undertaken because no new rule is proposed. Latest supplied headlines establish no previously validated Catalyst trigger. Next research run September 5 00:00 UTC; existing IONS/MIRM informational job #9 next 00:30 UTC per supplied schedule.

Existing-research trading review. Premise 1: live notes/observations/analyses/lessons show #19 remains latest supply strategy, rejecting re-entry for absent reproducible cost-inclusive chronological OOS entry/exit calibration. No newer validated rule is returned. Premise 2: live trade ledger contains only two closed operator-liquidated lots; monitor #4 done, no pending/open exposure. These selected exogenous exits cannot estimate natural payoff distribution or validate stops/targets. Premise 3: issuer source reopened https://www.frontlineplc.cy/fro-second-quarter-and-six-months-2026-results/ retains strong booked rates and ballast-day qualification; repeat reading adds no independent evidence. Conclusion: retain $278.67 cash; no entry, exit or adjustment. Validity: missing mandated numerical edge implies zero eligible size. Soundness bounded by unreviewed historical raw artifacts and absence of a broad fresh-news scan; this does not prove tanker stocks will fall. Counterexample: strong rates could support further gains, but do not identify expected win/loss or attainable exits. Start flat, goal repeatable positive net returns, binding constraint audited implementation and OOS calibration. Quarter-Kelly undefined; policy notional zero. Qualitative consequence chain: freight scarcity can favor owners over charterers; ballast/utilization alters realized earnings; equity gains further depend on valuation and entry/exit timing. No fresh backtest, statistical fit or Monte Carlo run because no new rule is proposed and assumed payoff inputs would not repair missing evidence. No eligible signal or exposure needs a new monitor/job before September 5 00:00 UTC research. Sources: query_research/query_trades/list_monitors fund=supply September 4 21:18 UTC; supplied account snapshot; issuer URL above. Prior automatic-buy notes remain superseded.

Premise 1: live Quant memory read in notes/observations/analyses/lessons order contains no adopted executable rule after strategy #17; superseded GTLB notes #4/#7 stay inactive. Premise 2: saved backtest #10 reports 20-session holdout -30.23%, five-session holdout -6.38%, selected full sample seven completed events, last-three holdout and omitted costs. Inherited figures, not recomputed this run. Premise 3: current query_trades fund=quant and list_monitors fund=quant confirm zero active/pending orders and zero monitors; three closed forced exits already have lessons. Conclusion: keep $245.69 cash; no entry, exit or adjustment. Validity: mandate requires validated executable positive expectancy, absent here. Soundness limits: selected tiny holdout cannot disprove all PEAD; unavailable raw artifacts and natural-exit payoff distribution preclude reliable Kelly. Counterexamples: DELL's forced gain does not test planned horizon; future favorable headline or lower price could yield a gain but supplies no calibrated entry rule. Prior cash unchanged. Start flat; goal repeatable net gains; binding constraint preregistered broad chronological OOS validation with costs, actual entry/exit semantics and affordable cash-only lots. Quarter-Kelly undefined; policy size zero. Primary abstract https://arxiv.org/abs/2601.08962 reread this run supports efficient post-2016 post-announcement price formation, but uses a different strategy and is the same source, not independent confirmation of our holdout. Unsupported turnover benefits spread recipients; first order abstention avoids transaction costs, second preserves capital, third prevents funding pressure driving replacement risk. Fresh headline feed supplies no validated Quant rule; no claim about its issuer fundamentals is being acted on. No fresh backtest, Monte Carlo or indicator sweep undertaken for this unchanged rejected rule. No Quant monitor requires action before September 5 00:00 UTC research; job #8 remains informational per supplied schedule. Other funds' items are outside this review.

Explicit status resolution requested by CIO: September 2 backtest #5's ADOPT verdict is superseded for all live trading by WATCH, consistent with September 4 analysis #15. Historical reported returns are retained as exploratory evidence only. Premise 1: source audit this run of /app/agent/dist/backtest/strategies.js and engine.js confirms prior-20 CLOSE breakout, same-signal-close entries, immediate flat signal otherwise, exact stop/target fills, and no fees/slippage. Premise 2: #5 reports overlapping 180/365/730-day windows and parameter sweeps, not independent chronological holdouts; no hourly validation or win/payoff sample calibration is recorded. Three overlapping windows are not three independent validations. Premise 3: live ledger has one forced BTC liquidation, no open/pending/closing lots; an exogenous exit cannot identify average natural win/loss. Premise 4: September 4 21:06 UTC primary venue data shows indicative BTC 79779.0295 vs next-close threshold 81269.4915, ETH 2453.254 vs 2515.933, SOL 101.845 vs 109.15, UNI 6.199495 vs 6.32576. September 3 completed BTC/UNI signals remain true; September 4 daily bar is incomplete. Sources https://runway.adityaperswal.workers.dev/data/crypto-bars and https://runway.adityaperswal.workers.dev/data/crypto-snapshots . Conclusion: no new entry, delayed re-entry, or queued breakout order is supported; quarter-Kelly undefined without calibrated payoffs, so allocation is $0. Strongest counterargument: positive BTC/SOL historical returns could reflect real momentum; they do not remedy selected windows or transaction-cost and timing defects. Validity: missing mandated validation implies ineligibility, not proof of negative expected return. Soundness: source behavior directly inspected and memory queried; raw old experiments unavailable, current top-volume ranking not established. Start $235.86 cash; goal positive net repeatable returns; binding constraint executable daily/hourly chronological net OOS validation with realistic exits. Official primary docs https://docs.alpaca.markets/us/reference/cryptobars-1 support Hour bars, so CLI daily-only support is not a data impossibility. Counterparties receive spreads if we trade prematurely; first order definition mismatch changes entries, second order same-close assumptions and turnover distort outcomes, third order false payoff calibration distorts size. No fresh backtest/simulation or broad catalyst research was performed because this is an unchanged-rule trading review. Job #10 remains research-only; monitor #8 is done. Remaining research includes independent holdout design, costs and slippage, measured-range exits, 15-minute enforcement and weekend stress.

Changed-state review of existing research. Premise 1: current query_research returns saved strategy #13 and six supply lessons; the older no-analysis statement in #13 was historical, not a current journal failure. No supply backtest artifact is in the returned analyses; filename searches of /tmp and /app/agent did not recover tanker holdout artifacts. This is limited search evidence, not proof that no artifact exists anywhere. Premise 2: query_trades fund=supply confirms only two operator-liquidated closed lots, FRO #6 and STNG #3; list_monitors fund=supply confirms #4 done. Two censored wins cannot establish average loss or independently validate the original exits. Premise 3: Frontline August 28 issuer release https://www.frontlineplc.cy/fro-second-quarter-and-six-months-2026-results/ reports strong Q3 contracted rates but explicitly expects lower full-quarter TCE due to ballast days. Contracted versus realized definitions reconcile apparent optimism and caution. Conclusion: retain $278.67 cash; propose no entry, exit or adjustment. Deduction is valid under the requirement for numerical validated edge; soundness is bounded by missing artifacts and selected two-trade history, and does not establish that tanker shares must fall. Strongest counterexample: rate strength could generate further equity gains, but this supplies neither calibrated win/loss estimates nor attainable exit levels. Start state flat, goal positive repeatable net returns, binding constraint reproducible cost-inclusive chronological OOS entry/exit calibration. Quarter-Kelly is undefined with available evidence; policy size is zero, not an estimated zero probability of success. Who benefits, qualitatively: shipowners may retain freight pricing power; charterers bear freight cost, while ballast days dilute recognized daily economics. First order: bookings improve visibility; second: utilization and ballast affect realized earnings; third: share returns still require valuation and entry/exit evidence. No fresh strategy, backtest or Monte Carlo was run in this trading review; simulating assumed edge would not cure the missing calibration. No actionable signal needs a job or monitor before 00:00 UTC research. Next regular equity open per venue context is September 8, not September 7.

Premise 1: fresh query_research notes, observations, analyses and lessons retains rejection #6/#16; ten-session run-up holdout -2.45%, 3 events, 33.3% wins, no new validated rule. These are previously recorded metrics, not a fresh backtest; pooled win/loss averages are not holdout calibration. Premise 2: live query_trades and list_monitors show flat Catalyst book, no queued orders, no due monitors; supplied capital $49.14. Premise 3: Kroger issuer page rechecked https://www.thekrogerco.com/ir-feed-item/kroger-announces-second-quarter-conference-call-with-investors/ confirms September 11 08:00 ET conference call only. Premise 4: latest IONS headline was already addressed by observation #43 and analysis #16; direct reopening https://ir.ionis.com/news-releases/news-release-details/ionis-partner-novartis-announces-lpahorizon-phase-3-topline failed in this run, so no new primary confirmation or new fact claimed. Conclusion: no entry, exit or adjustment proposal. Validity: uncalibrated positive edge implies zero size under mandate. Soundness limits: tiny selected holdout, unavailable raw artifacts this run, no current price measurements and no new source-wide news scan. Counterexample: a future catalyst rally could occur, but a possible rally does not validate the entry distribution. Start state cash; goal repeatable net gains; binding constraint positive implementable OOS edge. Quarter-Kelly cannot be reliably estimated, so size zero. Who benefits from an unsupported trade: counterparties collecting transaction costs. First order of abstaining: no new gap exposure; second: preserve deployable cash; third: allow independent validation before risking capital. No fresh backtest, simulation or technical sweep warranted for unchanged rejected rule in this trading review. Retain monitor #9 conditional research response; positive results/reaction require validation before proposal, guidance cuts or rejection mean pass. Next research run September 5 00:00 UTC per venue context.

Changed-state trading review, not a new backtest. Premise 1: live query_research fund=quant notes/observations/analyses/lessons contains no rule adopted after rejection #14; notes #4/#7 remain superseded by #64. Premise 2: backtest #10 reports selected next-open positive-surprise >=8% gap rule with seven completed 20-session events, last-three holdout -30.23%, five-session holdout -6.38%, and costs omitted. These are inherited results, not recomputed today. Premise 3: query_trades and list_monitors fund=quant at 21:06 UTC confirm zero active/pending positions and zero monitors. Conclusion: no proposal; retain $245.69 cash. Validity: no validated implementable positive edge implies zero size under mandate. Soundness limits: tiny selected holdout does not disprove all PEAD, and three operator exits cannot calibrate strategy win/loss probabilities or slippage. Counterexamples: DELL's profitable liquidation does not validate the intended horizon; a new headline or a cheaper entry might change future returns but does not supply a tested rule. Prior was cash; evidence did not change it. Start state flat; goal repeatable net positive expectancy; binding constraint broad preregistered chronological OOS validation with costs and actual venue entry/exit semantics. Do not derive positive Kelly from pooled pre-holdout winners. Source recheck https://arxiv.org/abs/2601.08962 supports efficient post-2016 post-announcement price formation but differs from our rule and is not independent confirmation of our specific holdout. Unsupported turnover benefits spread recipients; first-order avoiding entry avoids that cost, second-order preserves research capital, third-order prevents the monthly shortfall from weakening standards. No fresh backtest, indicator sweep or simulation is necessary for this unchanged rejected rule. Quant job #8 remains informational per supplied schedule; no validated signal requires an intervening watch or new order before 00:00 UTC.

Trading review of existing research, not a new backtest. Premise 1: query_trades confirms three closed Catalyst lots, no open or pending orders; current fund capital $49.14 per run context. Premise 2: saved backtest #6 rejects the ten-session pre-earnings rule: holdout -2.45%, N=3, 33.3% wins; pooled average win 7.69% and loss 3.62% cannot substitute for holdout payoff estimates. Premise 3: KR call September 11 08:00 ET is confirmed by issuer https://www.thekrogerco.com/ir-feed-item/kroger-announces-second-quarter-conference-call-with-investors/ ; monitor #9 remains armed. Premise 4: IONS primary release confirms pelacarsen endpoint failure: https://ir.ionis.com/news-releases/news-release-details/ionis-partner-novartis-announces-lpahorizon-phase-3-topline. Conclusion: no validated fresh run-up entry; size zero. Validity: these premises support rejecting the current rules, not all catalyst strategies. Soundness limits: tiny selected holdout; operator liquidations censor signal outcomes; no new quotes or OOS retest obtained because no new rule is proposed. Counterargument: some prior runs were profitable, but pooled winners do not establish current expected value. Start state cash; goal positive net repeatable returns; binding constraint validated edge. Quarter-Kelly cannot be reliably estimated; do not infer positive sizing from pooled returns. Execution ledger audit shows IONS/MIRM original reward/risk 1.40/1.08, both below 1.5; do not repair by inflating targets. Who benefits from an unsupported entry: counterparties receiving spread, while the fund bears unmeasured gaps. First-order implication of pelacarsen failure: reduced program expectations; second: pipeline valuation uncertainty; third: need company-wide review before future exposure. These are qualitative inferences, not measured valuation effects. Journal writes succeeded; six trade-linked lessons recorded.

Supersedes the execution eligibility of analysis #5, not its reported historical returns. Premise 1: source inspection of /app/agent/dist/backtest/strategies.js shows breakout is close[t] > maximum of prior 20 closes, returning flat immediately otherwise; it is not an intraday high breakout or a persistent Donchian channel position. Premise 2: engine.js enters on the same signal close, models exact stop/target prices and applies no fees or slippage. Premise 3: saved analysis #5 has daily parameter/window sweeps but no independent chronological holdout, hourly test, trade count, win rate or average win/loss. Conclusion: evidence cannot calibrate an executable positive edge; proposed size is zero. Valid deduction under mandate; it does not prove the strategy is unprofitable. Strongest counterargument is positive reported BTC/SOL historical returns, but selected frictionless results are insufficient. Start all cash, goal validated executable rule, binding constraint cost-adjusted daily/hourly OOS validation with next-bar fills. Exchanges/liquidity providers collect costs on false entries; first-order mismatch changes entry timing, second-order adds unmeasured turnover, third-order invalidates sizing. Current source data https://runway.adityaperswal.workers.dev/data/crypto-bars and https://runway.adityaperswal.workers.dev/data/crypto-snapshots fetched September 4 20:54 UTC. BTC and UNI had completed Sep 3 closing signals, contrary to blanket 'no signal' claims from the high-based watch; every current quote midpoint is below its current 20-completed-close threshold. Yesterday's signal does not validate a delayed entry today. Existing ten-name watchlist is not independently verified as today's top ten by volume.

Premise 1: Live query_trades and list_monitors show three closed quant trades, no active or queued orders, and no quant monitors. Premise 2: Saved backtest #10 rejects next-open positive-surprise >=8% gap PEAD: 20-session last-three holdout -30.23%, five-session holdout -6.38%, selected sample only seven completed events, costs omitted. Premise 3: No other quant rule has a recorded implementable validated edge. Conclusion: retain $245.69 deployable cash, proposed size zero; September 2 notes #4/#7 are superseded by September 4 analyses #10/#12. The three forced liquidations are execution outcomes, not tests of the intended 4-6 week horizon. Counterexample: DELL's profitable exit cannot rescue a strategy on three forced exits. Source: quant query_research analyses #10/#12 and query_trades #1/#7/#9, retrieved this run; https://arxiv.org/abs/2601.08962 rechecked September 4 supports post-2016 efficient post-announcement price formation. Binding constraint: broad preregistered chronological OOS validation net of fees/slippage for the actual venue-compatible rule. First order: avoid an unvalidated re-entry; second: preserve capital; third: require evidence rather than the monthly funding shortfall to change sizing. No fresh backtest was run in this trading review.

Premise 1: live query_research returns no supply analyses or lessons; earlier CIO summaries report an FRO holdout with an unrealistic swing target and a losing STNG holdout, but their underlying artifacts are unavailable in this journal. Premise 2: query_trades confirms only two closed trades, both operator liquidations, and no open or pending positions; supply monitor #4 is done. Premise 3: Frontline's 2026-08-28 issuer release confirms Q3 VLCC contracted TCE $156,900/day and 86% coverage (https://www.frontlineplc.cy/fro-second-quarter-and-six-months-2026-results/), evidence of revenue visibility, not a calibrated stock entry or exit. Conclusion: retain $278.67 cash, propose no re-entry. Validity: insufficient tested edge implies zero size under mandate. Soundness limitation: missing historical artifacts prevent independent holdout audit, and two exogenous exits cannot estimate average loss. Counterexample: continuing high freight rates may still raise shares, but does not supply win/loss calibration. Binding constraint: reproducible cost-inclusive out-of-sample rule with targets inside measured holding-period ranges; only then estimate quarter-Kelly. No new backtest warranted in this short trading review because no new rule is being proposed. Sources: runway query_research, query_trades and list_monitors fund=supply retrieved this run; issuer URL above.

Premise 1: classic SUE-decile PEAD is cross-sectional and often long-short; this venue used adjusted-EPS beat + guidance + positive gap, long-only. Premise 2: Martineau finds large-cap PEAD absent since 2006. Premise 3: 2026 tick research finds ~70% of price discovery within five minutes and post-2016 BBO returns 0.01% before latency. Premise 4: our next-open screen lost 30.2% in the last-three holdout. Conclusion is valid if these evidence sets map to liquid US names; soundness is limited by our small selected sample and differing signal definitions. First order: next-open buyers receive the residual after most information is priced. Second order: selecting large gaps concentrates reversal/tail risk; one -20.8% five-day loss erased six winners. Third order: stops do not protect opening gaps and apparent 4-6 week PEAD exposure is mostly unvalidated idiosyncratic risk. Who benefits: fast after-hours liquidity providers and informed traders; late market buyers pay the discovery premium. Binding constraint is a pre-registered, broad OOS sample showing positive net next-open returns. Current GTLB/DELL/SNOW must liquidate under operator directive; do not re-enter from this thesis.

On the seven qualified events with 20-day outcomes, OLS of SPY-adjusted 20-day return on opening gap and log(1+EPS surprise) gives gap coefficient -1.45, surprise coefficient +0.0083, R-squared 49.7%; simple gap/return correlation is -0.703 and log-surprise/return correlation -0.155. These estimates are descriptive only: N=7, heteroskedastic, a single HPE outcome is influential, universe chosen from current news/candidates, and adjusted-versus-GAAP EPS definitions conflict (e.g. GTLB). Counterexample: DELL Feb continued +28.0% over 20d after a 13.1% gap; HPE reversed -28.1% after 33.7%. Conclusion: neither larger gap nor larger headline surprise supports stronger expected drift here; if anything the gap may flag exhaustion. No sizing edge.

Hypothesis: long liquid US stocks at the next open when reported EPS surprise is positive and the opening gap is >=8%; hold 1/5/10/20 sessions. Method: 43 firm-quarters, Nasdaq reported surprise, Alpaca IEX adjusted OHLC; 8 qualified. Returns enter at next open and exit at close, benchmark SPY; 10 bp costs were not deducted (so results are optimistic). Results: 20d N=7, raw compound -10.69%, max sequential drawdown 41.05%, win 57.14%, average win 11.40%, average loss -15.61%; mean abnormal +1.14% but bootstrap 95% CI -11.27% to +14.16%. Chronological last-three holdout compounded -30.23% versus +28.01% earlier. At 5d, +9.16% compound and 85.7% wins, but one HPE loss was -20.76% and holdout lost 6.38%. Selection-biased universe and N=7 prevent broad inference, but the rule fails its own holdout. Reject; do not use this calibration to open or size trades.

Start state: biotech run-ups were sized around one documented PDUFA with exit 3-4 days before. Binding constraint: issuers and FDA control timing, not the calendar. First order: RARE lost 45.9% when a separately disclosed Phase 3 readout arrived inside the holding window; IONS received approval 19 days early and fell 5.3%. Second order: stops cannot cap overnight gaps and positive decisions can sell off. Third order: every biotech position needs a company-wide catalyst map through exit plus early-action stress; undated windows inside the hold make size zero unless intentionally accepted. MIRM must liquidate under operator directive; no substitute entry.

Primary-source screen: GME Sep 8 complete results are mostly de-risked informationally because preliminary figures disclose falling sales of $780-800M, operating income $150-170M, net income $290-310M, and $238M investment gains partly offset by $75M digital-asset losses; earnings quality and acquisition/convertible complexity dominate. ADBE Sep 10 combines earnings with a newly announced CEO succession, raising interpretation risk after a 9.8% run. KR Sep 11 enters with FY2026 adjusted EPS guidance $5.10-5.30 and 1-2% identical-sales growth, but historical pre-event drift is negative. Watch reactions; do not pre-position.